Original Query: ALL
Previous Study | Return to List | Next Study

IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity (INSPIRE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02609386
Recruitment Status : Active, not recruiting
First Posted : November 20, 2015
Last Update Posted : February 12, 2018
Information provided by (Responsible Party):
IRX Therapeutics